Cargando…
The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection
Systemic chronic active Epstein–Barr virus infection (sCAEBV) is an EBV-positive T- or NK-cell neoplasm revealing persistent systemic inflammation. Twenty-five percent of sCAEBV patients accompany angiopathy. It is crucial to clarify the mechanisms of angiopathy development in sCAEBV because angiopa...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019545/ https://www.ncbi.nlm.nih.gov/pubmed/35464987 http://dx.doi.org/10.3389/fmicb.2022.874998 |
_version_ | 1784689308619243520 |
---|---|
author | Ohashi, Ayaka Uemura, Yu Yoshimori, Mayumi Wada, Naomi Imadome, Ken-Ichi Yudo, Kazuo Koyama, Takatoshi Shimizu, Norio Nishio, Miwako Arai, Ayako |
author_facet | Ohashi, Ayaka Uemura, Yu Yoshimori, Mayumi Wada, Naomi Imadome, Ken-Ichi Yudo, Kazuo Koyama, Takatoshi Shimizu, Norio Nishio, Miwako Arai, Ayako |
author_sort | Ohashi, Ayaka |
collection | PubMed |
description | Systemic chronic active Epstein–Barr virus infection (sCAEBV) is an EBV-positive T- or NK-cell neoplasm revealing persistent systemic inflammation. Twenty-five percent of sCAEBV patients accompany angiopathy. It is crucial to clarify the mechanisms of angiopathy development in sCAEBV because angiopathy is one of the main causes of death. Interleukin-1β (IL-1β) is reported to be involved in angiopathy onset. We investigated if IL-1β plays a role as the inducer of angiopathy of sCAEBV. We detected elevated IL-1β levels in four out of 17 sCAEBV patient’s plasma. Interestingly, three out of the four had clinically associated angiopathy. None of the other patients with undetectable level of IL-1β had angiopathy. In all patients with high plasma levels of IL-1β and vascular lesions, EBV-infected cells were CD4-positive T cells. In one patient with high plasma IL-1β, the level of IL-1β mRNA of the monocytes was 17.2 times higher than the level of the same patient’s EBV-infected cells in peripheral blood. In Ea.hy926 cells, which are the models of vascular endothelial cells, IL-1β inhibited the proliferation and induced the surface coagulation activity. IL-1β is a potent biomarker and a potent therapeutic target to treat sCAEBV accompanying angiopathy. |
format | Online Article Text |
id | pubmed-9019545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90195452022-04-21 The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection Ohashi, Ayaka Uemura, Yu Yoshimori, Mayumi Wada, Naomi Imadome, Ken-Ichi Yudo, Kazuo Koyama, Takatoshi Shimizu, Norio Nishio, Miwako Arai, Ayako Front Microbiol Microbiology Systemic chronic active Epstein–Barr virus infection (sCAEBV) is an EBV-positive T- or NK-cell neoplasm revealing persistent systemic inflammation. Twenty-five percent of sCAEBV patients accompany angiopathy. It is crucial to clarify the mechanisms of angiopathy development in sCAEBV because angiopathy is one of the main causes of death. Interleukin-1β (IL-1β) is reported to be involved in angiopathy onset. We investigated if IL-1β plays a role as the inducer of angiopathy of sCAEBV. We detected elevated IL-1β levels in four out of 17 sCAEBV patient’s plasma. Interestingly, three out of the four had clinically associated angiopathy. None of the other patients with undetectable level of IL-1β had angiopathy. In all patients with high plasma levels of IL-1β and vascular lesions, EBV-infected cells were CD4-positive T cells. In one patient with high plasma IL-1β, the level of IL-1β mRNA of the monocytes was 17.2 times higher than the level of the same patient’s EBV-infected cells in peripheral blood. In Ea.hy926 cells, which are the models of vascular endothelial cells, IL-1β inhibited the proliferation and induced the surface coagulation activity. IL-1β is a potent biomarker and a potent therapeutic target to treat sCAEBV accompanying angiopathy. Frontiers Media S.A. 2022-04-06 /pmc/articles/PMC9019545/ /pubmed/35464987 http://dx.doi.org/10.3389/fmicb.2022.874998 Text en Copyright © 2022 Ohashi, Uemura, Yoshimori, Wada, Imadome, Yudo, Koyama, Shimizu, Nishio and Arai. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Ohashi, Ayaka Uemura, Yu Yoshimori, Mayumi Wada, Naomi Imadome, Ken-Ichi Yudo, Kazuo Koyama, Takatoshi Shimizu, Norio Nishio, Miwako Arai, Ayako The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection |
title | The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection |
title_full | The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection |
title_fullStr | The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection |
title_full_unstemmed | The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection |
title_short | The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection |
title_sort | plasma level of interleukin-1β can be a biomarker of angiopathy in systemic chronic active epstein–barr virus infection |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019545/ https://www.ncbi.nlm.nih.gov/pubmed/35464987 http://dx.doi.org/10.3389/fmicb.2022.874998 |
work_keys_str_mv | AT ohashiayaka theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT uemurayu theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT yoshimorimayumi theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT wadanaomi theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT imadomekenichi theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT yudokazuo theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT koyamatakatoshi theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT shimizunorio theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT nishiomiwako theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT araiayako theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT ohashiayaka plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT uemurayu plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT yoshimorimayumi plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT wadanaomi plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT imadomekenichi plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT yudokazuo plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT koyamatakatoshi plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT shimizunorio plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT nishiomiwako plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection AT araiayako plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection |